{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:17:54Z","timestamp":1790741874868,"version":"4.1.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The SUNSHINE and SUNRISE phase III trials demonstrated sustained clinical efficacy of secukinumab in patients with moderate-to-severe hidradenitis suppurativa (HS) through 52 weeks. Patients completing the core trials could enter a 4-year extension trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the long-term efficacy, safety\/tolerability and maintenance of clinical response to secukinumab through week 104 in the extension trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with a hidradenitis suppurativa (HS) clinical response (HiSCR) at week 52 of the core trials (extension trial baseline visit) entered a randomized withdrawal period. HiSCR responders receiving subcutaneous secukinumab 300\u2005mg every 2 or 4 weeks (SECQ2W\/SECQ4W) through week 52 in the core trials were randomized 2 : 1 to continue secukinumab (SECQ2W-R-Q2W or SECQ4W-R-Q4W) or receive placebo (SECQ2W-R-PBO or SECQ4W-R-PBO) through week 104. The primary endpoint was time to loss of response (LOR; newly defined for this trial) through week 104 in week 52 HiSCR responders (SECQ2W-R-Q2W vs. SECQ2W-R-PBO and SECQ4W-R-Q4W vs. SECQ4W-R-PBO). Time to LOR was tested at 1.25% (one-sided) for each comparison (one-sided familywise alpha of 2.5%) through week 104. If LOR was met, patients could remain in the trial on open-label secukinumab treatment. Additional endpoints included safety and HiSCR. The trial was registered with ClinicalTrials.gov (NCT04179175).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 84.3% of patients who completed the core trials entered the extension trial; 55.9% were week 52 HiSCR responders. The primary endpoint was not met for either secukinumab dosing regimen. The estimated risk reduction for LOR was 13% (SECQ2W-R-Q2W vs. SECQ2W-R-PBO; one-sided P = 0.25) and 30% (SECQ4W-R-Q4W vs. SECQ4W-R-PBO; one-sided P = 0.04). The median time to LOR was numerically longer in the secukinumab arms vs. placebo {SECQ2W-R-Q2W [283\u2005days; 95% confidence interval (CI) 176, \u2013] vs. SECQ2W-R-PBO [239\u2005days; 95% CI 120, \u2013]; SECQ4W-R-Q4W [365\u2005days 95% CI 225, \u2013] vs. SECQ4W-R-PBO [171\u2005days; 95% CI 113\u2013337]}. In week 52 HiSCR responders reporting LOR, 44% (SECQ2W-R-Q2W), 58% (SECQ2W-R-PBO), 40% (SECQ4W-R-Q4W) and 34% (SECQ4W-R-PBO) were achieving HiSCR at the time of LOR. Overall, the safety of secukinumab was consistent with the core trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The primary endpoint of this trial was not met. HiSCR was maintained in many patients at the time of LOR. The safety of secukinumab was consistent with the previously characterized safety profile in the core trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljae469","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T15:22:58Z","timestamp":1732720978000},"page":"629-640","source":"Crossref","is-referenced-by-count":19,"title":["Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial"],"prefix":"10.1093","volume":"192","author":[{"given":"Alexa B","family":"Kimball","sequence":"first","affiliation":[{"name":"Harvard Medical School and Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk G","family":"Bechara","sequence":"additional","affiliation":[{"name":"International Centre for Hidradenitis Suppurativa\/Acne Inversa (ICH), Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum , Bochum ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysha","family":"Badat","sequence":"additional","affiliation":[{"name":"Chris Hani Baragwanath Academic Hospital , Soweto, Gauteng ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4713-3911","authenticated-orcid":false,"given":"Evangelos J","family":"Giamarellos-Bourboulis","sequence":"additional","affiliation":[{"name":"4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice\u00a0B","family":"Gottlieb","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai , New York City, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor B E","family":"Jemec","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Zealand University Hospital , Roskilde ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad","family":"Reguiai","sequence":"additional","affiliation":[{"name":"Dermatology Department, Polyclinique Courlancy-Bezannes , Reims ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel P","family":"Villani","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Edouard Herriot Hospital, Hospices Civils de Lyon, Claude Bernard Lyon I University , Lyon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivette","family":"Alarcon","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Bansal","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gasperoni","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruvie","family":"Martin","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation , East Hanover, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Paguet","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Uhlmann","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hichem","family":"Zouater","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoba","family":"Ravichandran","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation , East Hanover, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsaneh","family":"Alavi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"2025031819361925300_ljae469-B1","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jaad.2019.08.089","article-title":"Hidradenitis suppurativa: current and emerging treatments","volume":"82","author":"Goldburg","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025031819361925300_ljae469-B2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/bjd\/ljad345","article-title":"Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape","volume":"190","author":"Krueger","year":"2024","journal-title":"Br J Dermatol"},{"key":"2025031819361925300_ljae469-B3","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11237240","article-title":"Current medical and surgical treatment of hidradenitis suppurativa \u2013 a comprehensive review","volume":"11","author":"Ocker","year":"2022","journal-title":"J Clin Med"},{"key":"2025031819361925300_ljae469-B4","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.amjmed.2022.09.025","article-title":"A practical guide for primary care providers on timely diagnosis and comprehensive care strategies for hidradenitis suppurativa","volume":"136","author":"Garg","year":"2023","journal-title":"Am J Med"},{"key":"2025031819361925300_ljae469-B5","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025031819361925300_ljae469-B6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11154-016-9328-5","article-title":"Evidence-based approach to the treatment of hidradenitis suppurativa\/acne inversa, based on the European guidelines for hidradenitis suppurativa","volume":"17","author":"Gulliver","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"key":"2025031819361925300_ljae469-B7","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamasurg.2021.3655","article-title":"Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial","volume":"156","author":"Bechara","year":"2021","journal-title":"JAMA Surg"},{"key":"2025031819361925300_ljae469-B8","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s13555-023-00935-x","article-title":"The current clinical trial landscape for hidradenitis suppurativa: a narrative review","volume":"13","author":"Hunt","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025031819361925300_ljae469-B9","author":"Novartis"},{"key":"2025031819361925300_ljae469-B10","author":"Novartis"},{"key":"2025031819361925300_ljae469-B11","author":"UCB"},{"key":"2025031819361925300_ljae469-B12","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"2025031819361925300_ljae469-B13","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jid.2020.10.014","article-title":"Unraveling the heterogeneity of hidradenitis suppurativa with phenotype schema","volume":"141","author":"Kirby","year":"2021","journal-title":"J Invest Dermatol"},{"key":"2025031819361925300_ljae469-B14","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jdin.2020.09.005","article-title":"Quantifying the natural variation in lesion counts over time in untreated hidradenitis suppurativa: implications for outcome measures and trial design","volume":"1","author":"Frew","year":"2020","journal-title":"JAAD Int"},{"key":"2025031819361925300_ljae469-B15","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/sim.3495","article-title":"A graphical approach to sequentially rejective multiple test procedures","volume":"28","author":"Bretz","year":"2009","journal-title":"Stat Med"},{"key":"2025031819361925300_ljae469-B16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bjd.18983","article-title":"Evidence for a \u2018window of opportunity\u2019 in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study","volume":"184","author":"Marzano","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025031819361925300_ljae469-B17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1159\/000508787","article-title":"Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system","volume":"236","author":"Kokolakis","year":"2020","journal-title":"Dermatology"},{"key":"2025031819361925300_ljae469-B18","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1111\/bjd.14038","article-title":"Diagnostic delay in hidradenitis suppurativa is a global problem","volume":"173","author":"Saunte","year":"2015","journal-title":"Br J Dermatol"},{"key":"2025031819361925300_ljae469-B19","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/ced.14448","article-title":"Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab","volume":"46","author":"Frew","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"2025031819361925300_ljae469-B20","first-page":"1518","article-title":"Switching from adalimumab originator to biosimilar in patients with hidradenitis suppurativa results in losses of response \u2013 data from the German HS Registry HSBest","volume":"12","author":"Kirsten","year":"2022","journal-title":"Life (Basel)"},{"key":"2025031819361925300_ljae469-B21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/ije\/dyh299","article-title":"Regression to the mean: what it is and how to deal with it","volume":"34","author":"Barnett","year":"2005","journal-title":"Int J Epidemiol"},{"key":"2025031819361925300_ljae469-B22","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/j.jaad.2020.07.040","article-title":"High placebo rates in clinical trials: is the problem scoring systems or drug efficacy?","volume":"83","author":"Kimball","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025031819361925300_ljae469-B23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaad.2019.05.065","article-title":"Exploring changes in placebo treatment arms in hidradenitis suppurativa randomized clinical trials: a systematic review","volume":"82","author":"Ali A","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025031819361925300_ljae469-B24","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjd.16672","article-title":"A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process","volume":"179","author":"Thorlacius","year":"2018","journal-title":"Br J Dermatol"},{"key":"2025031819361925300_ljae469-B25","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v102.563","article-title":"Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data","volume":"102","author":"Gottlieb","year":"2022","journal-title":"Acta Derm Venereol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae469\/60907367\/ljae469.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/4\/629\/60907367\/ljae469.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/4\/629\/60907367\/ljae469.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T15:36:29Z","timestamp":1742312189000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/192\/4\/629\/7913451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,11,29]]},"published-print":{"date-parts":[[2025,3,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae469","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,11,29]]}}}